the phase ivd of inactivated enterovirus 71 vaccine

Conditions: Hand, Foot and Mouth Disease (HFMD)

Summary: enterovirus 71 (ev71), a major pathogen causing hand-foot-and-mouth disease (hfmd) worldwide, is a member of the human enterovirus species a, family picornaviridae. its infection occasionally leads to severe diseases and death, with central nervous system (cns) damage. recently, except of inactivated vaccine, several ev71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. a formalin-inactivated ev71 vaccine (human diploid cell, kmb-17 cell) has been finished phase i, ii and iii clinical trials and licensed by sfda in china at dec. 3, 2015. based on the results of clinical trials, the protective efficacy of inactivated ev71 vaccine is 97% against hfmd caused by ev71. the phase iv clinical trial has been carried out from july 2016. the purpose of phase ivd is to evaluated the immunogenicity and safety of the inactive ev71 vaccine within two measles attenuated live vaccine and live attenuated japanese encephalitis vaccine at the same time point in large scale population of chinese children (8 months old) in guangdong province, china.

there are two parts of phase ivd clinical trials have been performed. first, to evaluate the immunogenicity of the inactive ev71 vaccine within two measles attenuated live vaccine and live attenuated japanese encephalitis vaccine at the same time point in large scale population of chinese children (8 months old), within 56-day-post-immunized. second, to safety of the inactive ev71 vaccine within two measles attenuated live vaccine and live attenuated japanese encephalitis vaccine at the same time point in large scale population of chinese children (8 months old), within 56-day-post-immunized.

Eligibility criteria:
inclusion criteria: * healthy subjects (6-71 months old children) as established by medical history and clinical examination * the subjects' legal guardian must be aware of this vaccines * the subjects' legal guardian voluntarily participate in the study and signed informed consent form * subjects with temperature ≤ 37.0 ℃ * the subjects' legal guardian with the ability and objective to comply with the requirements of the protocol * persist for a 14-month visit (and receive blood, stool (or specimens by means of a swab) tests according to program requirements in immunogenicity observation group) exclusion criteria: * allergy or serious side-effects to a vaccine or any ingredient of vaccine * epilepsy, seizures, convulsions, neurological illness * congenital or hereditary immunodeficiency * autoimmune disease * asthma, thyroidectomy, angioneurotic edema, diabetes or cancer * asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy * clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder * acute illness or acute exacerbation of chronic disease in last 7 days * any prior administration of immunodepressant or corticosteroids in last 6 months * any prior administration of blood products in last 3 months * any prior administration of live-attenuated vaccine in last 15 days * any prior administration of subunit or inactivated vaccines in last 7 days * fever before vaccination, axillary temperature ﹥37.0 ℃ * the laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, wbc, platelets), blood biochemistry tests (alt, total bilirubin, direct bilirubin, cr, bun) and urine tests (urine protein, urine sugar, blood cells), etc. * hypertension or hypotension. systolic blood pressure ﹥140 mmhg and/ or diastolic blood pressure ﹥90 mmhg; systolic blood pressure ﹤90 mmhg and/or diastolic blood pressure ﹤60 mmhg * any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives * take part into other vaccine or drug clinical trials in last half year

Keywords: hand, foot and mouth disease (hfmd) immunogenicity safety